C: Use with warning if Rewards outweigh pitfalls. Animal reports clearly show risk and human scientific tests not accessible or neither animal nor human scientific tests done.
pentobarbital will lower the extent or influence of lonafarnib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Lonafarnib is actually a delicate CYP3A4 substrate. Coadministration with solid or reasonable CYP3A4 inducers is contraindicated.
Warning when discontinuing CYP3A4 inducers which have been coadministered with hydrocodone; plasma concentrations of hydrocodone may perhaps maximize and may result in perhaps fatal respiratory depression
pentobarbital will reduce the level or result of alprazolam by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep track of.
pentobarbital will reduce the extent or result of isradipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Significance Unidentified.
pentobarbital will reduce the level or outcome of iloperidone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep track of.
pentobarbital will decrease the level or influence of clozapine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
pentobarbital will decrease the extent or effect of montelukast by impacting website hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Significance Mysterious.
pentobarbital will lower the level or effect of piroxicam by impacting hepatic enzyme CYP2C9/ten metabolism. Small/Significance Unidentified.
pentobarbital will minimize the extent or impact of celecoxib by influencing hepatic enzyme CYP2C9/ten metabolism. Small/Importance Not known.
Contraindicated (1)pentobarbital will reduce the extent or influence of lorlatinib by influencing hepatic/intestinal enzyme CYP3A4 metabolism.
With therapeutic doses of TCAs, barbiturates increase metabolism and reduce blood concentrations of TCAs.
Contraindicated. CYP3A4 is liable for the development and elimination of cariprazine's Energetic metabolites. The effect of CYP3A4 inducers on cariprazine exposure has not been evaluated plus the net influence is unclear.
pentobarbital will reduce the level or effect of alosetron by impacting hepatic enzyme CYP2C9/ten metabolism. Minimal/Importance Not known.